The latest price target for Novartis (NYSE:NVS) was reported by Barclays on January 6, 2026. The analyst firm set a price target for $0.00 expecting NVS to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Novartis (NYSE:NVS) was provided by Barclays, and Novartis upgraded their equal-weight rating.

The last upgrade for Novartis AG happened on January 6, 2026 when Barclays raised their price target to N/A. Barclays previously had an underweight for Novartis AG.

The last downgrade for Novartis AG happened on September 12, 2025 when Goldman Sachs changed their price target from $119 to $118 for Novartis AG.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novartis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novartis was filed on January 6, 2026 so you should expect the next rating to be made available sometime around January 6, 2027.

While ratings are subjective and will change, the latest Novartis (NVS) rating was a upgraded with a price target of $0.00 to $0.00. The current price Novartis (NVS) is trading at is $148.96, which is out of the analyst’s predicted range.